StockMirror — Stock Screener

CIPLA Q2 FY27 Results & Earnings Analysis

Sentiment: Good (Confidence: medium)

Earnings Summary

Cipla reported Q2 FY27 revenue of INR7,404 crores (+4% QoQ) with India delivering highest-ever quarterly revenue (+12% YoY, branded Rx +15% beating market 14.3%), US at $172M (+$10M QoQ), and EMEU $101M. EBITDA margin (ex-other income) at 18.7% (+200 bps QoQ) and PAT margin 11.9% (+77 bps QoQ) with gross margin 64.4% (+7% QoQ) on improved mix. Management maintained US $1B exit run-rate and 18.5-20% EBITDA margin guidance, expecting sequential margin improvement in H2 driven by Ventolin ramp-up, Q3 Advair launch, and 3 pending launches (2 respiratory, 1 peptide). Strategic progress: first DPI approval (generic Advair), Qilu Pembrolizumab biosimilar partnership for North America (2029 patent expiry), CTTQ HER2 ADC in-licensing, 45-50 US filings planned over 3 years, 4 biosimilars under development. Risks: Pithampur 7 Form 483 observations (OAI, no repeats/DI), South Africa tender loss (favorable court ruling), trade generics mid-single-digit YoY, consumer cost/pricing headwinds. Net cash INR9,823 crores; ETR guided 27-27.5%.

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

Management maintains both US $1B exit run-rate (growth) and 18.5-20% EBITDA margin guidance, expecting sequential margin improvement while investing in launches and R&D; 200 bps QoQ margin expansion achieved alongside 4% QoQ revenue growth. Higher R&D (6-7%) and launch investments balanced with marg

About Cipla Limited

Cipla Limited (CIPLA) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More